Already compatible with the previous-generation G6, Mobi now pairs with Dexcom’s latest-generation CGM. San Diego-based Tandem launched Mobi, the world’s smallest, durable automated insulin delivery (AID) system in the U.S. this year. It received FDA clearance for people with diabetes ages six and up in July 2023.
Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. It comes in at less than half the size of the existing Tandem pump system, the t:slim X2 pump. Mobi can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve.
It features Control-IQ technology, an advanced hybrid closed-loop automated insulin delivery feature that predicts and helps prevent high and low blood sugar. Control-IQ leads to improved time in range throughout the day and night.
“Choice is a hallmark of our offerings, and we’ve proven this commitment with the expansion of our insulin pump portfolio and extended CGM compatibilities,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “With this integration, we’re providing more flexibility for our customers and continuing our decade-long partnership with Dexcom to bring innovative and discrete solutions to people living with diabetes.”
More about the integration of Tandem Mobi and Dexcom G7
The company says the new integration makes it the only company offering two insulin pumps connecting with both G6 and G7. Tandem’s t:slim X2 pump with Control-IQ, also an AID, alongside Mobi, gives users more choice in diabetes management. t:slim X2 added G7 integration in December 2023, becoming the first AID system to pair with the CGM.
According to a news release, Tandem plans to email all Mobi users in the U.S. in the coming weeks when they have an available software update. Users can follow the instructions in the email to add the new feature, free of charge, by remote software upgrade. The company already began shipping Mobi pumps pre-loaded with the updated software to new customers.
G7 features a 60% size reduction from the previous generation, the G6. It offers a 30-minute warmup period (down from waiting two hours for glucose readings to begin in the past).
The CGM provides more information in one place with personalized insights, extended-wear design and more. It features a simple wear experience, starting with unscrewing a cap. The user then puts the sensor on their body and pushes a button. The device is then turned on and can be paired with a smartphone. It received FDA clearance in 2022.
Integrating G7 into Mobi gives users more time in closed loop with the CGM’s 30-minute warm-up time. It also features additional discretion with G7’s low-profile, all-in-one wearable frame.
“As the leader in connectivity, Dexcom has been the CGM of choice for the development of AID systems for over a decade,” said Jake Leach, EVP and COO at Dexcom. “We are proud to offer people with diabetes the ability to use Dexcom G7, our smallest and most accurate CGM, with Tandem Mobi to create a seamless user experience.”
